The potential for markers of epithelial-mesenchymal transition to improve colorectal cancer outcomes: A systematic review

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 7, 2014, Pages 1164-1175

  Busch, Evan L ^a   McGraw, Kathleen A ^c   Sandler, Robert S ^a,b  

^a IL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYTOKERATIN; FIBRONECTIN; INTEGRIN; MICRORNA; NERVE CELL ADHESION MOLECULE; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR ZEB1; TRANSCRIPTION FACTOR ZEB2; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN;

CANCER RISK; CANCER SURVIVAL; CLINICAL EVALUATION; COLORECTAL CANCER; DISEASE ASSOCIATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; MEASUREMENT ACCURACY; META ANALYSIS (TOPIC); METASTASIS; OUTCOME ASSESSMENT; PHENOTYPE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; SAMPLE SIZE; SURVIVAL RATE; SYSTEMATIC REVIEW;

EID: 84904001948     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-0017     Document Type: Review

References (55)

1. Weinberg RA. The biology of cancer. New York: Garland Science; 2007.
2. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119: 1420-8.
3. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 2003;15: 740-6.
4. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 2009;119: 1429-7.
5. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144: 646-74.
6. Li Y, Zhu X, Zeng Y, Wang J, Zhang X, Ding YQ, et al. FMNL2 enhances invasion of colorectal carcinoma by inducing epithelial-mesenchymal transition. Mol Cancer Res 2010;8: 1579-90.
7. Pino MS, Kikuchi H, Zeng M, Herraiz MT, Sperduti I, Berger D, et al. Epithelial to mesenchymal transition is impaired in colon cancer cells with microsatellite instability. Gastroenterology 2010;138: 1406-7.
8. Benson AB III, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004;22: 3408-9.
9. Janda E, Lehmann K, Killisch I, Jechlinger M, Herzig M, Downward J, et al. Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J Cell Biol 2002;156: 299-13.
10. Radisky DC. Epithelial-mesenchymal transition. J Cell Sci 2005;118: 4325-6.
11. AHRQ. Avoiding bias in selecting studies. [accessed 2014 March 27 2014]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK126701/.
12. Hashimoto Y, Skacel M, Adams JC. Association of loss of epithelial syndecan-1 with stage and local metastasis of colorectal adenocarcinomas: an immunohistochemical study of clinically annotated tumors. BMC Cancer 2008;8: 185.
13. Lv Q, Wang W, Xue J, Hua F, Mu R, Lin H, et al. DEDD interacts with PI3KC3 to activate autophagy and attenuate epithelial-mesenchymal transition in human breast cancer. Cancer Res 2012;72: 3238-0.
14. Matsushita K, Toiyama Y, Tanaka K, Saigusa S, Hiro J, Uchida K, et al. Soluble CXCL16 in preoperative serum is a novel prognostic marker and predicts recurrence of liver metastases in colorectal cancer patients. Ann Surg Oncol 2012;19: S518-7.
15. Meng HM, Zheng P, Wang XY, Liu C, Sui HM, Wu SJ, et al. Overexpression of nanog predicts tumor progression and poor prognosis in colorectal cancer. Cancer Biol Ther 2010;9: 295-02.
16. Steller EJ, Raats DA, Koster J, Rutten B, Govaert KM, Emmink BL, et al. PDGFRB promotes liver metastasis formation of mesenchymal-like colorectal tumor cells. Neoplasia 2013;15: 204-7.
17. Zhou WJ, Geng ZH, Chi S, Zhang W, Niu XF, Lan SJ, et al. Slit-Robo signaling induces malignant transformation through Hakai-mediated E-cadherin degradation during colorectal epithelial cell carcinogenesis. Cell Res 2011;21: 609-6.
18. Zhu W, Cai MY, Tong ZT, Dong SS, Mai SJ, Liao YJ, et al. Overexpression of EIF5A2 promotes colorectal carcinoma cell aggressiveness by upregulating MTA1 through C-myc to induce epithelialmesenchymaltransition. Gut 2012;61: 562-75.
19. Kouso H, Yano T, Maruyama R, Shikada Y, Okamoto T, Haro A, et al. Differences in the expression of epithelial-mesenchymal transition related molecules between primary tumors and pulmonary metastatic tumors in colorectal cancer. Surg Today 2013;43: 73-80.
20. Fan XJ, Wan XB, Huang Y, Cai HM, Fu XH, Yang ZL, et al. Epithelialmesenchymal transition biomarkers and support vector machine guided model in preoperatively predicting regional lymph node metastasis for rectal cancer. Br J Cancer 2012;106: 1735-1.
21. Mitrovic B, Schaeffer DF, Riddell RH, Kirsch R. Tumor budding in colorectal carcinoma: time to take notice. Mod Pathol 2012;25: 1315-5.
22. Ohtsuki K, KoyamaF, Tamura T, Enomoto Y, Fujii H, Mukogawa T, et al. Prognostic value of immunohistochemical analysis of tumor budding in colorectal carcinoma. Anticancer Res 2008;28: 1831-6.
23. Kevans D, Wang LM, Sheahan K, Hyland J, O'Donoghue D, Mulcahy H, et al. Epithelial-mesenchymal transition (EMT) protein expression in a cohort of stage II colorectal cancer patients with characterized tumor budding and mismatch repair protein status. Int J Surg Pathol 2011; 19: 751-60.
24. Mesker WE, Liefers GJ, Junggeburt JMC, Van Pelt GW, Alberici P, Kuppen PJK, et al. Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients. Cell Oncol 2009;31: 169-78.
25. Oshiro R, Yamamoto H, Takahashi H, Ohtsuka M, Wu X, Nishimura J, et al. C4.4A is associated with tumor budding and epithelial-mesenchymal transition of colorectal cancer. Cancer Sci 2012;103: 1155-64.
26. Khanh do T, Mekata E, Mukaisho K, Sugihara H, Shimizu T, Shiomi H, et al. Transmembrane mucin MUC1 overexpression and its association with CD10() myeloid cells, transforming growth factor-beta1 expression, and tumor budding grade in colorectal cancer. Cancer Sci 2013;104: 958-64.
27. Spaderna S, Schmalhofer O, Hlubek F, Berx G, Eger A, Merkel S, et al.A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology 2006; 131: 830-0.
28. Zlobec I, Bihl MP, Foerster A, Rufle A, Lugli A. The impact ofCpGisland methylator phenotype and microsatellite instability on tumour budding in colorectal cancer. Histopathology 2012;61: 777-87.
29. Knosel T, Emde V, Schluns K, Schlag PM, Dietel M, Petersen I. Cytokeratin profiles identify diagnostic signatures in colorectal cancer using multiplex analysis of tissue microarrays. Cell Oncol 2006; 28: 167-75.
30. Harbaum L, Pollheimer MJ, Kornprat P, Lindtner RA, Rehak P, Hoefler G, et al. Keratin 7 expression in colorectal cancer -Freak of nature or significant finding? Ann Oncol 2010;21: i38.
31. Koelzer VH, Karamitopoulou E, Dawson H, Kondi-Pafiti A, Zlobec I, Lugli A. Geographic analysis of RKIP expression and its clinical relevance in colorectal cancer. Br J Cancer 2013;108: 2088-96.
32. Ono H, Imoto I, Kozaki K, Tsuda H, Matsui T, Kurasawa Y, et al. SIX1 promotes epithelial-mesenchymal transition in colorectal cancer through ZEB1 activation. Oncogene 2012;31: 4923-4.
33. Loboda A, Nebozhyn MV, Watters JW, Buser CA, ShawPM, HuangPS, et al. EMT is the dominant program in human colon cancer. BMC Med Genomics 2011;4: 9.
34. Bellovin DI, Bates RC, Muzikansky A, Rimm DL, Mercurio AM. Altered localization of p120 catenin during epithelial to mesenchymal transition of colon carcinoma is prognostic for aggressive disease. Cancer Res 2005;65: 10938-5.
35. Bellovin DI, Simpson KJ, Danilov T, Maynard E, Rimm DL, Oettgen P, et al. Reciprocal regulation of RhoA and RhoC characterizes the EMT and identifies RhoC as a prognostic marker of colon carcinoma. Oncogene 2006;25: 6959-67.
36. Fan XJ, Wan XB, Yang ZL, Fu XH, Huang Y, Chen DK, et al. Snail promotes lymph node metastasis and Twist enhances tumor deposit formation through epithelial-mesenchymal transition in colorectal cancer. Hum Pathol 2013;44: 173-80.
37. Fujikawa H, Tanaka K, Toiyama Y, Saigusa S, Inoue Y, Uchida K, et al. High TrkB expression levels are associated with poor prognosis and EMT induction in colorectal cancer cells. J Gastroenterol 2012;47: 775-84.
38. Knosel T, Chen Y, Hotovy S, Settmacher U, Altendorf-Hofmann A, Petersen I. Loss of desmocollin 1-3 and homeobox genes PITX1 and CDX2 are associated with tumor progression and survival in colorectal carcinoma. Int J Colorectal Dis 2012;27: 1391-9.
39. Kroepil F, Fluegen G, Vallbohmer D, Baldus SE, Dizdar L, Raffel AM, et al. Snail1 expression in colorectal cancer and its correlation with clinical and pathological parameters. BMC Cancer 2013;13: 145.
40. Liu Z, Sun B, Qi L, Li H, Gao J, Leng X. Zinc finger E-box binding homeobox 1 promotes vasculogenic mimicry in colorectal cancer through induction of epithelial-To-mesenchymal transition. Cancer Sci 2012;103: 813-0.
41. Saito S, Okabe H, Watanabe M, Ishimoto T, Iwatsuki M, Baba Y, et al. CD44v6 expression is related to mesenchymal phenotype and poor prognosis in patients with colorectal cancer. Oncol Rep 2013; 29: 1570-8.
42. Shioiri M, Shida T, Koda K, Oda K, Seike K, Nishimura M, et al. Slug expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients. Br J Cancer 2006;94: 1816-2.
43. Toquet C, Colson A, Jarry A, Bezieau S, Volteau C, Boisseau P, et al. ADAM15 to (alpha)5(beta)1 integrin switch in colon carcinoma cells: a late event in cancer progression associated with tumor dedifferentiation and poor prognosis. Int J Cancer 2012;130: 278-87.
44. Yu H, Jin GZ, Liu K, Dong H, Yu H, Duan JC, et al. Twist2 is a valuable prognostic biomarker for colorectal cancer. World J Gastroenterol 2013;19: 2404-1.
45. Bates RC, Bellovin DI, Brown C, Maynard E, Wu B, Kawakatsu H, et al. Transcriptional activation of integrin (beta)6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest 2005;115: 339-7.
46. Kahlert C, Klupp F, Brand K, Lasitschka F, Diederichs S, Kirchberg J, et al. Invasion front-specific expression and prognostic significance of microrna in colorectal liver metastases. Cancer Sci 2011;102: 1799-807.
47. Meng X, Wu J, Pan C, Wang H, Ying X, Zhou Y, et al. Genetic and epigenetic downregulation of MicroRNA-12 promotes colorectal tumor metastasis via dysregulation of MnSOD. Gastroenterology 2013;145: 426-6.e1-6.
48. Gomez I, Pena C, Herrera M, Munoz C, Larriba MJ, Garcia V, et al. TWIST1 is expressed in colorectal carcinomas and predicts patient survival. PLoS ONE 2011;6: e18023.
49. Franci C, Gallen M, Alameda F, Baro T, Iglesias M, Virtanen I, et al. Snail1 protein in the stroma as a new putative prognosis marker for colon tumours. PLoS ONE 2009;4: e5595.
50. Kahlert C, Lahes S, Radhakrishnan P, Dutta S, Mogler C, Herpel E, et al. Overexpression of ZEB2 at the invasion front of colorectal cancer is an independent prognostic marker and regulates tumor invasion in vitro. Clin Cancer Res 2011;17: 7654-63.
51. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012; 62: 220-1.
52. Zlobec I, Lugli A. Invasive front of colorectal cancer: dynamic interface of pro-/anti-Tumor factors. World J Gastroenterol 2009;15: 5898-906.
53. Szklo M. Population-based cohort studies. Epidemiol Rev 1998;20: 81-90.
54. Qu P, Chu H, Ibrahim JG, Peacock J, Shen XJ, Tepper J, et al. Statistical strategies to improve the efficiency of molecular studies of colorectal cancer prognosis. Br J Cancer 2008;99: 2001-5.
55. Rizzardi AE, Johnson AT, Vogel RI, Pambuccian SE, Henriksen J, Skubitz AP, et al. Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring. Diagn Pathol 2012;7: 42.